Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas

[1]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[2]  A. Elkahloun,et al.  Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. , 2015, The Journal of clinical investigation.

[3]  J. Zucman‐Rossi,et al.  Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis , 2014, Hepatology.

[4]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[5]  Jessica Zucman-Rossi,et al.  Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. , 2014, Cancer cell.

[6]  Koichiro Tamura,et al.  MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. , 2013, Molecular biology and evolution.

[7]  J. Zucman‐Rossi,et al.  Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.

[8]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[9]  Na Zhao,et al.  Recurrent Targeted Genes of Hepatitis B Virus in the Liver Cancer Genomes Identified by a Next-Generation Sequencing–Based Approach , 2012, PLoS genetics.

[10]  K. L. La Perle,et al.  Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[12]  Angela M. Liu,et al.  Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma , 2012, Nature Genetics.

[13]  Pei-Rong Wang,et al.  Induction of hepatocellular carcinoma by in vivo gene targeting , 2012, Proceedings of the National Academy of Sciences.

[14]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[15]  J. Bruix,et al.  Hepatocellular carcinoma , 2012, The Lancet.

[16]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[17]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[18]  A. Rezai,et al.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial , 2011, The Lancet Neurology.

[19]  P. Moore,et al.  Why do viruses cause cancer? Highlights of the first century of human tumour virology , 2010, Nature Reviews Cancer.

[20]  E. Wang,et al.  Analysis and design of RNA sequencing experiments for identifying isoform regulation , 2010, Nature Methods.

[21]  M. Buendia,et al.  Mechanisms of HBV-related hepatocarcinogenesis. , 2010, Journal of hepatology.

[22]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[23]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[24]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[25]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[26]  James M. Wilson,et al.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. , 2009, The Journal of infectious diseases.

[27]  J. Maguire,et al.  Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.

[28]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[29]  J. Gutkind,et al.  Human tumor-associated viruses and new insights into the molecular mechanisms of cancer , 2008, Oncogene.

[30]  Mark J. Smyth,et al.  The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.

[31]  R. H. Smith,et al.  Adeno-associated virus integration: virus versus vector , 2008, Gene Therapy.

[32]  Daniel G. Miller,et al.  AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma , 2007, Science.

[33]  R. Owens,et al.  Preferential Integration of Adeno-Associated Virus Type 2 into a Polypyrimidine/Polypurine-Rich Region within AAVS1 , 2007, Journal of Virology.

[34]  E. Furth,et al.  Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  J. Emerson,et al.  Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. , 2006, Human gene therapy.

[36]  M. Gonçalves Adeno-associated virus: from defective virus to effective vector , 2005, Virology Journal.

[37]  T. Flotte,et al.  Adeno-associated virus: a ubiquitous commensal of mammals. , 2005, Human gene therapy.

[38]  P. Hinds,et al.  Cyclins and cdks in development and cancer: a perspective , 2005, Oncogene.

[39]  Cristel G. Thomas,et al.  Germline hepatocyte nuclear factor 1α and 1β mutations in renal cell carcinomas , 2005 .

[40]  Yoshiki Murakami,et al.  Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene , 2003, Oncogene.

[41]  R. Haberman,et al.  Novel Transcriptional Regulatory Signals in the Adeno-Associated Virus Terminal Repeat A/D Junction Element , 2000, Journal of Virology.

[42]  C. Bréchot,et al.  Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon Hepatitis B virus genome insertion , 1998, Oncogene.

[43]  T. Flotte,et al.  Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes. , 1996, Human gene therapy.

[44]  M. Nei,et al.  Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. , 1993, Molecular biology and evolution.

[45]  D. Housman,et al.  Targeted integration of adeno‐associated virus (AAV) into human chromosome 19. , 1991, The EMBO journal.

[46]  C. Bréchot,et al.  Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma , 1990, Nature.

[47]  M. Rocchi,et al.  Site-specific integration by adeno-associated virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[48]  F. Corpet Multiple sequence alignment with hierarchical clustering. , 1988, Nucleic acids research.

[49]  A. Hope A Simplified Monte Carlo Significance Test Procedure , 1968 .

[50]  B. Casto,et al.  Adenovirus-Associated Defective Virus Particles , 1965, Science.